Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”
Mark Rishniw et al · Oxford University Press · 2022
A de novo nonsense variant in the DMD gene associated with X‐linked dystrophin‐deficient muscular dystrophy in a cat
Acceso al recurso
Entrá al contenido desde la opción principal o elegí otra fuente disponible.
Acceso abierto disponible
Cómo citar
Elegí el formato que necesitás y copiá la referencia al portapapeles.
APA 7
al, M. R. E. (2022). Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”. https://doi.org/10.1111/jvim.16495
MLA
al, Mark Rishniw et. "Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”." 2022. https://doi.org/10.1111/jvim.16495.
Chicago
al, Mark Rishniw et. 2022. "Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”.". https://doi.org/10.1111/jvim.16495.
Harvard
al, M. R. E. 2022, Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”, Oxford University Press, available at: https://doi.org/10.1111/jvim.16495 [Accessed 29 Jun. 2026].
Detalles del recurso
Información bibliográfica útil para confirmar que se trata del material correcto.
- Título
- Letter regarding “ALVAC‐fIL2, a feline interleukin‐2 immunomodulator, as a treatment for sarcoids in horses: A pilot study”
- Autor / colaboradores
- Mark Rishniw et al
- Editorial
- Oxford University Press
- Año de publicación
- 2022
- ISSN
- 0891-6640
- ISSN
- 0891-6640
- Idioma
- eng